肺癌类器官在肺癌精准医学的应用及其研究进展
Application and Research Progress of Lung Cancer Organoid in Precision Medicine for Lung Cancer
黄志诚 1李博文 1王亚东 1薛剑超 1魏泽文 2梁乃新 1李单青1
作者信息
- 1. 100730 北京,中国医学科学院,北京协和医学院,北京协和医院胸外科
- 2. 100081 北京,北京理工大学医学技术学院生物医学工程系
- 折叠
摘要
分子检测技术的不断进步极大地推动了肺癌精准医学的发展,但是肿瘤的异质性与肿瘤的转移、复发和耐药密切相关,并且具有同一基因突变的不同肺癌患者采用不同的治疗策略会呈现出一定的疗效差异,因此现代精准医学的发展亟需通过个性化的肿瘤模型来精准制定个性化的治疗策略.肺癌类器官(lung cancer organoid,LCO)能够高度模拟肿瘤在体内的生物学特征,促进抗体药物偶联物等创新药物在肺癌精准医学的应用.随着LCO与肿瘤微环境共培养模型和微流控芯片等组织工程技术的发展,LCO可以更好地保留肿瘤组织的生物学特征和功能,进一步提高高通量和自动化药物敏感性实验.本文结合了最新的LCO研究进展,总结了LCO在肺癌精准医学中的应用进展与挑战.
Abstract
The continuous advancement of molecular detection technology has greatly propelled the develop-ment of precision medicine for lung cancer.However,tumor heterogeneity is closely associated with tumor metastasis,recurrence,and drug resistance.Additionally,different lung cancer patients with the same genetic mutation may exhibit varying treatment responses to different therapeutic strategies.Therefore,the development of modern precision medicine urgently requires the precise formulation of personalized treatment strategies through personalized tumor models.Lung cancer organoid(LCO)can highly simulate the biological characteristics of tumor in vivo,facilitating the application of innovative drugs such as antibody-drug conjugate in precision medicine for lung cancer.With the development of co-culture model of LCO with tumor microenvironment and tissue engineering technology such as microfluidic chip,LCO can better preserve the biological characteristics and functions of tumor tissue,further improving high-throughput and automated drug sensitivity experiment.In this review,we combine the latest research progress to summarize the applica-tion progress and challenges of LCO in precision medicine for lung cancer.
关键词
肺肿瘤/类器官/精准医学Key words
Lung neoplasms/Organoid/Precision medicine引用本文复制引用
基金项目
北京协和医院中央高水平医院临床科研专项(2022-PUMCH-B-011)
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据